Stocks / Apollo Hospitals Enterprise (APOLLOHOSP)

APOLLOHOSP Share Price, Analysis & News

Apollo Hospitals Enterprise (APOLLOHOSP) — Updated on 2026-05-08

Apollo Hospitals Enterprise operates within the healthcare facilities industry, providing integrated services. The company's business model encompasses hospital services and the sale of pharma and wellness products through its pharmacy network. Investors closely monitor Apollo Hospitals Enterprise share price for insights into the company's performance and its position within the evolving healthcare sector. Analysis of Apollo Hospitals Enterprise often focuses on its operational efficiency, revenue streams from its diverse healthcare offerings, and its ability to navigate sector trends and financial results. The company's integrated approach aims to cater to a wide range of patient needs, influencing its market valuation and investor interest.
Overview Daily Weekly

Key Takeaway

APOLLOHOSP shows strong bullish momentum with a 68.67 RSI and 10.59% monthly return, but its price near the upper Bollinger Band suggests potential overextension.

Daily

2026-05-08
  • The stock is experiencing a strong bullish trend and momentum, evidenced by its price trading above key moving averages, a high RSI of 68.67, and a bullish MACD crossover. This technical strength has propelled the stock to its 52-week high, with recent returns showing a 3.38% gain in the last day and a significant 10.59% in the last month, implying sustained investor confidence.
  • Despite the positive technicals, the price trading above the upper Bollinger Band suggests a potential for overextension and increased volatility in the short term, indicating that the current upward momentum might be nearing a point of consolidation or correction.
  • Fundamentally, the company shows robust growth, with year-over-year revenue increasing by 17.188% and net profit by 36.148%. This strong performance, coupled with quarter-over-quarter improvements in revenue, profit, and EPS, suggests a healthy underlying business that supports the current stock price appreciation.
  • Analysts maintain a largely positive outlook, with 92.3% of ratings being 'Strong Buy' or 'Buy', and this sentiment has been stable over the past month. This consensus among analysts reinforces the bullish case, implying that the market expects continued positive performance from the company.
  • Institutional investors, holding 65.38% of the company's shares, have shown a slight reallocation, with FIIs reducing their stake by 0.92% and DIIs increasing theirs by 1.26% in the last quarter. This shift within institutions, while maintaining overall high ownership, suggests a nuanced view on the stock's future prospects among different investor types.
Open daily analysis

Weekly

Latest weekly signal
  • The stock price rose 6.1% this week, supported by a 39.6% surge in trading volume that indicates increased market participation.
  • Momentum indicators are strengthening, with the Relative Strength Index (RSI, a measure of price movement speed) reaching 68.67 and the MACD line remaining above the signal line.
  • Apollo Hospitals achieved 100% ownership of its subsidiary, Apollo Health and Lifestyle Limited, following an acquisition of 775,744 shares for Rs 18.69 crore.
  • The company reported strong financial growth for the quarter ending December 2025, with net profit increasing 36.1% year-over-year to 516.0.
  • India Ratings and Research revised the outlook on the company's debt instruments to Positive from Stable, citing the planned demerger of its digital pharmacy business.
Open weekly analysis

Quarterly

Latest quarterly update
Detailed analysis available on the full page.

Price & Technical Structure

  • The stock has shown strong short-term returns, with a 3.38% gain in the last day and 10.59% in the last month.
  • The trend is bullish, indicated by a positive trend alignment score of 3 and the price trading above the 50-day EMA.
  • Momentum is strong, with an RSI of 68.67 and a bullish MACD crossover.
  • Volatility is elevated, with the price trading above the upper Bollinger Band, suggesting potential overextension.
  • The stock is at its 52-week high, with 0.0% distance from the high and a maximum drawdown of -15.21% in the past year.
The stock exhibits a strong bullish trend and momentum, evidenced by its price trading above key EMAs, a high RSI, and a bullish MACD signal. It has also achieved its 52-week high, indicating significant upward price action. However, the price is trading above the upper Bollinger Band, suggesting a potentially overextended condition and increased volatility. The recent returns have been robust, particularly over the last month and quarter.

Weekly Momentum

  • The stock price rose 6.1% this week, supported by a 39.6% surge in trading volume that indicates increased market participation.
  • Momentum indicators are strengthening, with the Relative Strength Index (RSI, a measure of price movement speed) reaching 68.67 and the MACD line remaining above the signal line.
  • Apollo Hospitals achieved 100% ownership of its subsidiary, Apollo Health and Lifestyle Limited, following an acquisition of 775,744 shares for Rs 18.69 crore.
  • The company reported strong financial growth for the quarter ending December 2025, with net profit increasing 36.1% year-over-year to 516.0.
  • India Ratings and Research revised the outlook on the company's debt instruments to Positive from Stable, citing the planned demerger of its digital pharmacy business.
Apollo Hospitals experienced a week of strong upward momentum, characterized by a 6.1% price gain and a significant increase in trading volume. The stock is currently trading above its 50-day and 200-day moving averages, reflecting a consistent positive trend. This market performance aligns with solid fundamental growth, as the company reported a 36.1% year-over-year increase in net profit for the quarter ending December 2025. Corporate developments, including the acquisition of full ownership in a subsidiary and a positive credit rating outlook, have further supported investor sentiment despite a recent downgrade to a hold rating by some market observers.